Medidata Solutions, a provider of clinical trial solutions, today announced the launch of Medidata Developer Central, a Web-based community that supports developers? efforts to integrate their clinical trial solutions with Medidata Rave, an electronic data capture (EDC), clinical data management (CDM), and reporting system.
MEDIDATA SOLUTIONS LAUNCHES ONLINE DEVELOPER COMMUNITY TO FOSTER COLLABORATIVE INNOVATION
Medidata Developer Central Supports Developers Using the Medidata Rave Web Services API
to Independently Build New Integrations with the Medidata Rave Platform
NEW YORK, N.Y. – October 27, 2008 – Medidata Solutions, a leading provider of clinical trial solutions, today announced the launch of Medidata Developer Central, a Web-based community that supports developers’ efforts to integrate their clinical trial solutions with Medidata Rave®, an industry-leading electronic data capture (EDC), clinical data management (CDM) and reporting system. This unique online venue provides a collaborative environment where innovative technology and service providers, as well as sponsors, can gain expertise to integrate solutions – such as interactive voice response (IVR), electronic patient reported outcomes (ePRO) and clinical trial management tools – with Medidata Rave. Developer Central simplifies the development path and makes it easy for sponsors of clinical research to extend Rave’s core platform capabilities to maximize the value of their current and future technology investments.
The launch of Medidata Developer Central extends the support of Medidata’s Rave Web Services API, which Medidata made available in June to enable independent, rapid and cost-effective integrations so that customers can enjoy a seamless eClinical environment with real-time, inbound and outbound data sharing using industry standards. Medidata Rave offers industry-leading clinical systems interoperability with its standards-based design – a design that has exclusively earned Rave CDISC certification for all eight operational data model (ODM) use cases.
Medidata created Developer Central in response to the growing demand from technology providers and contract research organizations (CROs) to integrate other technology solutions with Medidata Rave. Developer Central also addresses the industry’s rising number of IT developers relying on Web-based tools and online communities for their software development. A number of developers from clinical technology providers have already joined Medidata Developer Central as pilot members, including individuals from the following innovative companies:
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.